Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
Rates of regional- and distant-stage prostate cancer increasing in the U.S. among men aged ≥50 years.
FDA has approved rucaparib for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in men previously treated with androgen-receptor directed therapy and taxane-based chemotherapy.
Combination radiation treatment and radical prostatectectomy Gleason 9 to 10 prostate cancer are associated with similar cancer-specific mortality, a study found.
In a retrospective study, addition of carboplatin to chemotherapy regimens improved survival in men with metastatic castration-resistant prostate cancer whose disease progressed on second-generation hormone therapy.
Findings from a new study can help individualize prognoses for men with biochemical recurrence of prostate cancer after radical prostatectomy.
Cytoreductive radical prostatectomy following neoadjuvant androgen-deprivation therapy (ADT) in men with hormone-naïve low-volume metastatic prostate cancer improves survival long-term vs ADT alone, a study found.
Obese men with metastatic castration-resistant prostate cancer have superior cancer-specific and overall survival than their overweight and normal-weight counterparts, a study found.
